Overcoming endocrine therapy resistance by signal transduction inhibition.
暂无分享,去创建一个
[1] G. Tortora,et al. A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer , 2005, Clinical Cancer Research.
[2] M. Ellis,et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results , 2005 .
[3] M. Ellis,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.
[4] R. Sutherland,et al. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI‐277 on inhibition of MCF‐7 breast cancer cell‐cycle progression , 2003, International journal of cancer.
[5] W. Friedrichs,et al. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Mita,et al. Mammalian target of rapamycin: a new molecular target for breast cancer. , 2003, Clinical breast cancer.
[8] W. Carney,et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] I. Bièche,et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[11] D. DeMets,et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Lipton,et al. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. , 2002, Oncology reports.
[13] J. Massagué,et al. Breast cancer banishes p27 from nucleus , 2002, Nature Medicine.
[14] Alfonso Bellacosa,et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.
[15] L. Elit. CCI-779 Wyeth. , 2002, Current opinion in investigational drugs.
[16] Jinha M. Park,et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Nicholson,et al. Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer , 2002, Annals of the New York Academy of Sciences.
[18] W. Carney,et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Kurokawa,et al. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Johnston,et al. Farnesyl transferase inhibitors--a novel therapy for breast cancer. , 2001, Endocrine-related cancer.
[22] M. Dowsett. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.
[23] R. Nicholson,et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. , 2001, Endocrine-related cancer.
[24] P. Frost,et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.
[25] F. Kern,et al. Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .
[26] K. Mokbel,et al. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[27] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[29] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[30] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Lenferink,et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.
[32] W. R. Bishop,et al. Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules* , 2000, The Journal of Biological Chemistry.
[33] J. Slingerland,et al. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] L. Dirix,et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] G. Prendergast,et al. Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.
[36] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[37] P. Dombernowsky,et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Dowsett,et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[40] A Howell,et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Sliwkowski,et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.
[42] F. Kern,et al. MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.
[43] A. Levinson,et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.
[44] W. McGuire,et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. , 1992, Journal of the National Cancer Institute.
[45] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[46] Rakesh Kumar,et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody , 2004, Breast Cancer Research and Treatment.
[47] H. Kurokawa,et al. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] R. Schiff,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] D. Constantinidou,et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. , 2001, The Journal of biological chemistry.
[50] A. Oh,et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. , 2001, Molecular endocrinology.